Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Image 2-Enspryng™ (satralizumab-mwge).jpg
Satralizumab is a recombinant humanised monoclonal antibody that targets IL-6 receptor activity. Credit: Business Wire.